JPS63277065A - Plasma separation method - Google Patents
Plasma separation methodInfo
- Publication number
- JPS63277065A JPS63277065A JP11173087A JP11173087A JPS63277065A JP S63277065 A JPS63277065 A JP S63277065A JP 11173087 A JP11173087 A JP 11173087A JP 11173087 A JP11173087 A JP 11173087A JP S63277065 A JPS63277065 A JP S63277065A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- separator
- blood
- physiological saline
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000926 separation method Methods 0.000 title claims description 17
- 239000012528 membrane Substances 0.000 claims description 15
- 239000002504 physiological saline solution Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 description 52
- 239000012510 hollow fiber Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000002616 plasmapheresis Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、血漿交換療法における患者あるいは採漿者へ
の悪影響を防ぐための血漿分離法に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a plasma separation method for preventing adverse effects on patients or samplers during plasmapheresis therapy.
［従来の技術］
近年、難治性疾患の血漿交換療法か臨床応用され効果を
挙げつつある。この血漿交換療法においては施療前に血
液回路ならびに血漿分離器を生理食塩水にて充分に洗浄
、置換し、その後血液取り出し用チューブあるいは針等
と接続し血漿交換が開始される。[Prior Art] In recent years, plasmapheresis therapy for intractable diseases has been clinically applied and is becoming effective. In this plasma exchange therapy, the blood circuit and plasma separator are sufficiently washed and replaced with physiological saline before treatment, and then a blood removal tube or needle is connected to start plasma exchange.
［発明が解決しようとする問題点］
しかしながら、このような従来の血漿交換療法にあって
は、患者あるいは採漿者の抗原抗体反応が促進され、治
療あるいは採漿による悪影響が問題となる。[Problems to be Solved by the Invention] However, in such conventional plasmapheresis therapy, the antigen-antibody reaction of the patient or the plasma sample is promoted, resulting in the problem of adverse effects due to the treatment or plasma collection.
［問題点を解決するための手段］
そこで本発明では、上記問題点を解決するため生理食塩
水による血液回路および血漿分離器の洗浄置換後に予め
ヒト新鮮血漿による血漿分離器のコーティングを施すこ
とを見出し、本発明に到達したものである。すなわち、
本発明によれば、生理食塩水により血液回路および血漿
分離器を充分に洗浄した後、採取あるいは廃棄血漿の置
換液として使用されるヒト新鮮血漿を前記血漿分離器内
に流通させることにより、血漿分離器にヒト新鮮血漿に
よる分離膜コーティングを施した後、血漿分離操作を行
なうことを特徴とする血漿分離法、が提供される。[Means for Solving the Problems] Therefore, in the present invention, in order to solve the above problems, the plasma separator is coated with fresh human plasma in advance after cleaning and replacing the blood circuit and plasma separator with physiological saline. This is the heading that led to the present invention. That is,
According to the present invention, after thoroughly washing the blood circuit and the plasma separator with physiological saline, fresh human plasma, which is used as a replacement solution for collected or discarded plasma, is passed through the plasma separator. A plasma separation method is provided, which comprises coating a separator with a separation membrane with fresh human plasma and then performing a plasma separation operation.
本発明では、生理食塩水による血液回路および血漿分離
器の洗浄置換後、予めヒト新鮮血漿による血漿分離器の
コーティングを施すことにその特徴を有している。ここ
で、分離膜コーティングに使用するヒト新鮮血漿として
は、特に患者自身のものか好ましい。市販のヒト新鮮血
漿を使用する場合、患者に対しては非自己の蛋白質であ
り、場合によっては抗原抗体反応が起こる可能性がある
からである。The present invention is characterized in that after cleaning and replacing the blood circuit and plasma separator with physiological saline, the plasma separator is coated with fresh human plasma in advance. Here, the fresh human plasma used for coating the separation membrane is preferably the patient's own blood plasma. This is because when commercially available fresh human plasma is used, it is a non-self protein for the patient, and an antigen-antibody reaction may occur depending on the case.
また、本発明においては、血漿採取の実施に当り、血液
の抗凝固剤を適量使用する必要かある。Furthermore, in the present invention, it is necessary to use an appropriate amount of a blood anticoagulant when collecting plasma.
抗凝固剤としては体外血液潅流に使用できるものであれ
ばいずれでもよく、例えば、クエン酸（へ〇Ｄ、ＣＰＤ
等）、ヘパリン、プロスタグランジン、ＦＯＹ、ＭＤ−
８０５等が使用される。これらはその特性により献血者
へ注射によって投与することもてきる他、送血ラインに
分枝な設け、そこから持続投γ器あるいは点滴で投与す
ることも可能である。Any anticoagulant that can be used for extracorporeal blood perfusion may be used, such as citric acid (H〇D, CPD).
etc.), heparin, prostaglandin, FOY, MD-
805 etc. are used. Depending on their properties, they can be administered to blood donors by injection, or they can also be provided as a branch in the blood supply line and administered from there via a continuous injector or drip.
また、本発明の血漿分離器としては、血漿分離速度が大
で、血漿蛋白質の透過性が良好ないずれの脱型血漿分離
器も使用可能であり、中空糸膜型の分離膜モジュールを
使用することが好ましい。Further, as the plasma separator of the present invention, any typed plasma separator that has a high plasma separation rate and good plasma protein permeability can be used, and a hollow fiber membrane type separation membrane module can be used. It is preferable.
血漿分離膜モジュールに用いられる中空糸膜としては、
親木性を有するものが好ましく用いられるか、他方、元
来は疎水性であっても、界面活性剤又はコーティング剤
等により親木化処理したものも好ましく使用できる。更
に、疎水性の中空糸膜な水と相溶性がよく表面張力の小
さい、例えばアルコールの如き物質によって洗浄し、生
理食塩水のような無菌水、無塵水にて充填しておき、使
用に際して血液と置換することによって本発明の中空糸
膜として用いることができる。Hollow fiber membranes used in plasma separation membrane modules include:
Those having wood-philic properties are preferably used, while those that are originally hydrophobic but have been treated to become wood-friendly with a surfactant or coating agent can also be preferably used. Furthermore, the membrane is a hydrophobic hollow fiber membrane that is highly compatible with water and has a low surface tension, and is cleaned with a substance such as alcohol, and filled with sterile water such as physiological saline or dust-free water before use. It can be used as the hollow fiber membrane of the present invention by replacing it with blood.
また、中空糸の材質としては特に制限されるものではな
い。高分子材料を素材とするものの例としては、ポリオ
レフィン（高密度ポリエチレン、ポリプロピレン、ポリ
（４−メチル−ペンテン−１）など）、フッ素含有高分
子化合物、ポリスルホン、ポリカーボネート、ポリ塩化
ビニル、セルロースアセテート、ポリアクリロニトリル
、ポリビニルアルコール、ポリメチルメタアクリレート
、ポリアミド等の多孔質中空糸を挙げることができる。Further, the material of the hollow fibers is not particularly limited. Examples of polymer materials include polyolefins (high-density polyethylene, polypropylene, poly(4-methyl-pentene-1), etc.), fluorine-containing polymer compounds, polysulfone, polycarbonate, polyvinyl chloride, cellulose acetate, Examples include porous hollow fibers such as polyacrylonitrile, polyvinyl alcohol, polymethyl methacrylate, and polyamide.
また無機材料を素材とするものの例としては、ガラス、
セラミックス、炭素等の多孔質中空糸を挙げることがで
きる。以上のうち、耐溶血性が高い点から、ポリオレフ
ィンを素材とする膜が好ましい。多孔質中空糸の外径、
周壁部厚さ、孔径も特に制限されるものではないが、一
般には外径が約１０〜約１０００ ｕＬｍ 、周壁部厚
さが約１０〜約５００ ｇｔａ 、孔径が約０．０１〜
約７終１のものが好ましい。Examples of materials made from inorganic materials include glass,
Examples include porous hollow fibers made of ceramics, carbon, and the like. Among the above, membranes made of polyolefin are preferred from the viewpoint of high hemolysis resistance. Outer diameter of porous hollow fiber,
The thickness of the peripheral wall and the diameter of the pores are not particularly limited, but generally the outer diameter is about 10 to about 1000 uLm, the thickness of the peripheral wall is about 10 to about 500 gta, and the pore diameter is about 0.01 to about 1000 gta.
About 7 to 1 is preferred.
［実施例］
以下、本発明を実施例に基き詳細に説明するが、本発明
が実施例に限られるものでないことは明らかであろう。[Examples] Hereinafter, the present invention will be described in detail based on Examples, but it will be clear that the present invention is not limited to the Examples.
（実施例１）
イヌ新鮮血液ならびにイヌ新鮮血漿を使用し、生理食塩
水のみで置換する従来法と、生理食塩水ｌ換後に新鮮血
漿にて置換するした本発明の実施例について、各タンパ
ク成分の濾過率（篩い係数、Ｓ、Ｃ，）ならびに白血球
の経時的変動、および補体系を代表するＣＨｓｏ値につ
いて比較検討した。尚、実験には第１図（置換回路）及
び第２図（血漿交換回路）に示す回路を使用した。(Example 1) Regarding the conventional method in which fresh dog blood and fresh dog plasma are used and replacement with physiological saline alone, and the example of the present invention in which replacement with fresh plasma after 1 exchange of physiological saline, each protein component The filtration rate (sieving coefficient, S, C,), temporal changes in white blood cells, and CHso value, which represents the complement system, were compared and studied. In addition, the circuits shown in FIG. 1 (replacement circuit) and FIG. 2 (plasma exchange circuit) were used in the experiment.
第１図において、ｌは血漿分離器、２はイヌ新鮮血漿用
採漿バッグ、３は生理食塩水貯蔵タンク、４はポンプ、
Ｖｌおよびｖ２は三方活栓である。まず、従来法におい
ては三方活栓ｖｌを開放し、生理食塩水のみで回路およ
び血漿分離器ｌの洗浄、ご換を実施した。一方、本発明
においては、当初は従来法と同様に生理食塩水にて置換
し、その後に、イヌ新鮮血漿１２０ｍＭを使用して血漿
分離器ｌの分＃膜の血漿コーティングを実施した。In FIG. 1, 1 is a plasma separator, 2 is a blood sampling bag for fresh dog plasma, 3 is a saline storage tank, 4 is a pump,
Vl and v2 are three-way stopcocks. First, in the conventional method, the three-way stopcock vl was opened, and the circuit and plasma separator l were washed and replaced with only physiological saline. On the other hand, in the present invention, the plasma was initially replaced with physiological saline as in the conventional method, and then 120 mM of fresh dog plasma was used to coat the separation membrane of the plasma separator I with plasma.
従来法および本発明方法ともに、上記洗浄、置換操作を
行なった後、第２図に示す血漿交換回路により血漿流量
１００ｍＭにて血漿交換を実施した。第２図において、
５は加熱器、６および７はポンプを示す。In both the conventional method and the method of the present invention, after the above washing and replacement operations were performed, plasma exchange was performed at a plasma flow rate of 100 mM using the plasma exchange circuit shown in FIG. In Figure 2,
5 is a heater, and 6 and 7 are pumps.
尚、血漿分離器ｌの分離）模としては、ポリプロピレン
製中空糸膜（宇部興産■製、膜孔径ｏ、５ＪＬｍ、外径
４３０ｇｍ、内径３３０ＪＬｍ、空隙率７３％）を使用
した。A polypropylene hollow fiber membrane (manufactured by Ube Industries, Ltd., membrane pore diameter o, 5 JLm, outer diameter 430 gm, inner diameter 330 JLm, porosity 73%) was used as a model for plasma separator I (separation).
結果を表１に示す。The results are shown in Table 1.
（以丁、余白）
表１から明らかなように、本発明のごとく血漿を実際の
血漿交換操作実施前に血漿分離器の分離膜にコーティン
グすることによって、補体活性、白血球数への影響か軽
減され、なおかっ、各種成分の篩い係数および濾過量の
向上が認められた。(Explanation, margins) As is clear from Table 1, by coating the separation membrane of the plasma separator with plasma before performing the actual plasmapheresis operation as in the present invention, there is no effect on complement activity and white blood cell count. Furthermore, improvements in the sieving coefficient and filtration rate of various components were observed.
［発明の効果コ
以上説明したように、本発明の血漿分離法によれば、生
理食塩水による血液回路および血漿分離器の洗浄置換後
に予めヒト新鮮血漿による血漿分離器のコーティングを
行なうため、補体活性、白血球数への悪影響が軽減され
、治療に際しての悪影響を防止でき、しかも、各種成分
の篩い係数および濾過量も向上するという利点を有する
。[Effects of the Invention] As explained above, according to the plasma separation method of the present invention, the plasma separator is coated with fresh human plasma in advance after washing and replacing the blood circuit and plasma separator with physiological saline. It has the advantage of reducing adverse effects on body activity and white blood cell counts, preventing adverse effects during treatment, and improving the sieving coefficient and filtration rate of various components.
第１図は血漿の置換回路を示す説明図、第２図は血漿交
換回路を示す説明図である。
１−・・血漿分離器、２・・・新鮮血漿用採漿バッタ、
３・・・生理食塩水の貯蔵タンク、５・・・加熱器。FIG. 1 is an explanatory diagram showing a plasma replacement circuit, and FIG. 2 is an explanatory diagram showing a plasma exchange circuit. 1- Plasma separator, 2... Plasma collection locust for fresh plasma,
3... Physiological saline storage tank, 5... Heater.
Claims (2)
分に洗浄した後、採取あるいは廃棄血漿の置換液として
使用されるヒト新鮮血漿を前記血漿分離器内に流通させ
ることにより、血漿分離器にヒト新鮮血漿による分離膜
コーティングを施した後、血漿分離操作を行なうことを
特徴とする血漿分離法。(1) After thoroughly cleaning the blood circuit and plasma separator with physiological saline, fresh human plasma, which is used as a replacement solution for collected or discarded plasma, is passed through the plasma separator. A plasma separation method characterized by performing a plasma separation operation after coating a separation membrane with fresh human plasma.
範囲第１項記載の血漿分離法。(2) The plasma separation method according to claim 1, wherein the fresh human plasma is the patient's own plasma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11173087A JPS63277065A (en) | 1987-05-08 | 1987-05-08 | Plasma separation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11173087A JPS63277065A (en) | 1987-05-08 | 1987-05-08 | Plasma separation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63277065A true JPS63277065A (en) | 1988-11-15 |
Family
ID=14568721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11173087A Pending JPS63277065A (en) | 1987-05-08 | 1987-05-08 | Plasma separation method |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63277065A (en) |
-
1987
- 1987-05-08 JP JP11173087A patent/JPS63277065A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5858238A (en) | Salvage of autologous blood via selective membrane/sorption technologies | |
| JP4059543B2 (en) | Medical device for extracorporeal treatment of blood or plasma and method for manufacturing the device | |
| US4981596A (en) | System for treating blood for autotransfusion | |
| JP4453248B2 (en) | Method for producing hollow fiber membrane and hollow fiber membrane module | |
| JPH06104118B2 (en) | Platelet collection system | |
| JP3011463B2 (en) | Therapeutic blood purification apparatus and method for producing transfusion for hemodiafiltration (HDF) | |
| JP3899128B2 (en) | Apparatus and method for biospecific removal of heparin | |
| JP3172542B2 (en) | Filter material for capturing leukocytes and method for producing the same | |
| SE452336B (en) | PROCEDURE FOR DISPOSAL OF DISEASE-BREATHING MICROORGANISMS WHICH ADSORBATED EXTRACORPORAL ON A SELECTIVE BINDING ADSORBENT | |
| EP0728491B1 (en) | Method of producing a blood transfusion device | |
| JPS63277065A (en) | Plasma separation method | |
| JP3208132B2 (en) | Blood component separation method | |
| CN206577183U (en) | The plasmapheresis device extracorporeal circulation pipeline of changeable blood separator | |
| JPS5921813Y2 (en) | Blood granulocyte collection filter | |
| CN221803864U (en) | Device for evaluating thrombus formation of hemofilter | |
| JPH0197472A (en) | Multistage plasma separation method | |
| JP4833443B2 (en) | How to collect hematopoietic stem cells | |
| JPH04236959A (en) | Blood component separating system | |
| JPH01113068A (en) | plasma separator | |
| JPS6384560A (en) | plasma collection device | |
| JP3157519B2 (en) | Blood component separation system | |
| JPH02274262A (en) | Blood plasma collecting device | |
| JPH01113064A (en) | Priming method of plasma exchanger | |
| JPS63183071A (en) | Serum sampling device | |
| JPH0417861A (en) | plasma collection device |